{"id":"W1957081846","doi":"10.1111/j.1528-1167.2012.03441.x","title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first‐in‐class antiepileptic drug that targets KCNQ (K<sub>v</sub>7) potassium channels","year":2012,"lang":"en","type":"review","venue":"Epilepsia","topic":"Cardiac electrophysiology and arrhythmias","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Valeant Pharmaceuticals International; GlaxoSmithKline","keywords":"Urinary system; Medicine; Adverse effect; Placebo; Clinical trial; Urology; Internal medicine; Anesthesia; Pharmacology; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009676018,0.0009330739,0.003561716,0.0003356031,0.0003380115,0.00002401246,0.0002827899,0.0007147948,0.00006023032],"category_scores_gemma":[0.0002235152,0.0006246736,0.0009762418,0.0005195074,0.0006069231,0.0001579212,0.0003355064,0.001978874,0.00008780337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002126979,"about_ca_system_score_gemma":0.0004898881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008226532,"about_ca_topic_score_gemma":0.000004692766,"domain_scores_codex":[0.995708,0.0007633207,0.001096285,0.0008742482,0.0004158799,0.001142221],"domain_scores_gemma":[0.9961497,0.001653694,0.000763371,0.00101505,0.00008573216,0.0003324179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001750932,0.000833788,0.000444109,0.1130448,0.002219275,0.003060554,0.0006621857,0.000002978363,0.001477539,0.0006225205,0.02070638,0.855175],"study_design_scores_gemma":[0.002922775,0.001455281,0.00846204,0.02658478,0.003290926,0.002884321,0.0000263507,0.00003737323,0.002795313,0.0001469323,0.9502309,0.00116301],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01376237,0.9800426,0.000005181966,0.000466326,0.001442962,0.003167505,0.0001024643,0.00007552229,0.0009350553],"genre_scores_gemma":[0.04032808,0.9563935,0.0000490097,0.00009883804,0.001285773,0.000507984,0.0004402477,0.00014461,0.0007519666],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9295245,"threshold_uncertainty_score":0.9996204,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01039958907160417,"score_gpt":0.2460240838909757,"score_spread":0.2356244948193715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}